Evidence map›Paper›PMID 38110013›Full record

ArticleInternational journal of pharmaceutics2024

Development of nanoparticles based on amphiphilic cyclodextrins for the delivery of active substances.

Luc Augis, Ingeborg Nerbø Reiten, Jan-Lukas Førde, Juan M Casas-Solvas, Christina Sizun, Thomas Bizien, Ivan Rajkovic, Eric Larquet, Alexandre Michelet, Mayeul Collot and 3 more

Abstract read
In one paragraph

Article in International journal of pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Luc AugisUniversité Paris-Saclay, CNRS, Institut Galien Paris-Saclay, 91400 Orsay, France.
Ingeborg Nerbø ReitenCentre for Pharmacy, Department of Clinical Science, University of Bergen, Bergen, Norway.
Jan-Lukas FørdeCentre for Pharmacy, Department of Clinical Science, University of Bergen, Bergen, Norway; Department of Internal Medicine, Haukeland University Hospital, 5021 Bergen, Norway.
Juan M Casas-SolvasDepartment of Chemistry and Physics, University of Almería, Ctra de Sacramento s/n, E-04120 Almería, Spain.
Christina SizunUniversité Paris-Saclay, CNRS, Institut de Chimie des Substances Naturelles, UPR 2301, 91198 Gif-sur-Yvette, France.
Thomas BizienUniversité Paris-Saclay, Synchrotron Soleil, 91190 Saint-Aubin, France.
Ivan RajkovicSSRL, SLAC National Accelerator Lab, Menlo Park, CA, USA.
Eric LarquetLaboratoire de Physique de la Matière Condensée (PMC), CNRS, Ecole Polytechnique, Institut Polytechnique de Paris, 91120 Palaiseau, France.
Alexandre MicheletApplications Development Lab France, PerkinElmer, Villebon-sur-Yvette, France.
Mayeul CollotFaculté de Pharmacie, Laboratoire de Bioimagerie et Pathologies, UMR 7021 CNRS, Illkirch, France.
Sylviane LesieurUniversité Paris-Saclay, CNRS, Institut Galien Paris-Saclay, 91400 Orsay, France.
Lars HerfindalCentre for Pharmacy, Department of Clinical Science, University of Bergen, Bergen, Norway.
François-Xavier LegrandUniversité Paris-Saclay, CNRS, Institut Galien Paris-Saclay, 91400 Orsay, France. Electronic address: francois-xavier.legrand@universite-paris-saclay.fr.

Funding

A Synchrotron Radiation Structural Biology ResourcesP30GM133894 · NIGMS · STANFORD UNIVERSITY · PI Aina E. Cohen, KEITH O HODGSON · 2020 to 2026
$43.3M
PILATUS3 X 1M X-ray detectorS10OD021512 · OD · STANFORD UNIVERSITY · PI WEIS, WILLIAM I · 2016 to 2016
$550k
NIGMS NIH HHS P30 GM133894NIH HHS S10 OD021512
6 · The paper itself

Abstract

Although amphiphilic cyclodextrin derivatives (ACDs) serve as valuable building blocks for nanomedicine formulations, their widespread production still encounters various challenges, limiting large-scale manufacturing. This work focuses on a robust alternative pathway using mineral base catalysis to transesterify β-cyclodextrin with long-chain vinyl esters, yielding ACD with modular and controlled hydrocarbon chain grafting. ACDs with a wide range of degrees of substitution (DS) were reliably synthesized, as indicated by extensive physicochemical characterization, including MALDI-TOF mass spectrometry. The influence of various factors, including the type of catalyst and the length of the hydrocarbon moiety of the vinyl ester, was studied in detail. ACDs were assessed for their ability to form colloidal suspensions by nanoprecipitation, with or without PEGylated phospholipid. Small-angle X-ray scattering and cryo-electron microscopy revealed the formation of nanoparticles with distinct ultrastructures depending on the DS: an onion-like structure for low and very high DS, and reversed hexagonal organization for DS between 4.5 and 6.1. We confirmed the furtivity of the PEGylated versions of the nanoparticles through complement activation experiments and that they were well tolerated in-vivo on a zebrafish larvae model after intravenous injection. Furthermore, a biodistribution experiment showed that the nanoparticles left the bloodstream within 10 h after injection and were phagocytosed by macrophages.

Indexed as

CyclodextrinsNanoparticlesAnimalsCryoelectron MicroscopyEstersHydrocarbonsPolyethylene GlycolsTissue DistributionZebrafishCyclodextrinsEstersHydrocarbonsPolyethylene GlycolsAmphiphilic cyclodextrinComplement activationNanoparticlesPEGylationZebrafish larvae

Identifiers

PMID38110013
PMCPMC11641101

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.